Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 6/20 | 0.47 |
| ▸ | CCR9 | P51686 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 4/20 | 0.42 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161028 | 0.83 | MEN1 (0.42) | MEN1KMT2A | |
| SCHEMBL4166990 | 0.79 | HDAC1 (0.41) | MEN1KMT2A | |
| SCHEMBL1684278 | 0.77 | TP53 (0.38) | MEN1KMT2A | |
| SCHEMBL1684250 | 0.76 | KMT2A (0.42) | KMT2A | |
| SCHEMBL1684129 | 0.74 | POLB (0.42) | MEN1KMT2A | |
| SCHEMBL1684120 | 0.72 | MLNR (0.41) | MLNRCCR9PNMTHTR2CHTR2B | |
| SCHEMBL14542133 | 0.72 | MMP13 (0.44) | MEN1KMT2A | |
| SCHEMBL4165161 | 0.71 | MEN1 (0.44) | CYP2D6MEN1KMT2A | |
| SCHEMBL4158917 | 0.70 | LMNA (0.40) | MEN1KMT2A | |
| SCHEMBL15435386 | 0.70 | PNMT (0.77) | MLNRCCR9PNMTHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | claimed |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| EP-1943249-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | Pfizer Products Incorporated (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007039802-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER PRODUCTS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039802-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER PRODUCTS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, IMPA1, TYMP | MLNR 3832/4885CCR9 2547/4885PNMT 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.